BlossomHill Therapeutics Raises $84M in Series B Extension for Cancer Medicines Development

BlossomHill Therapeutics secures $84 million to accelerate development of lead clinical programs and advance cancer medicines portfolio

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here